<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001240</url>
  </required_header>
  <id_info>
    <org_study_id>890005</org_study_id>
    <secondary_id>89-DK-0005</secondary_id>
    <nct_id>NCT00001240</nct_id>
  </id_info>
  <brief_title>Evaluating Patients With Abnormal Levels of Gastric Acid</brief_title>
  <official_title>Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study is used by the Digestive Diseases Branch to evaluate patients with suspected&#xD;
      abnormalities in the secretion of gastric acid. The level of gastric acid is measured by&#xD;
      analyzing the gastric juices of each individual patient. The gastric acid sample is obtained&#xD;
      by a procedure known as nasogastric suctioning, where a thin plastic tube is passed from the&#xD;
      nose to the stomach.&#xD;
&#xD;
      Depending on the patient's present condition further diagnostic testing may be required to&#xD;
      achieve a diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an omnibus protocol used by the Digestive Diseases Branch to evaluate patients&#xD;
      with suspected abnormalities of gastric acid secretion. Gastric acid secretion is measured by&#xD;
      means of analysis of gastric juices obtained by nasogastric suction. Other clinically&#xD;
      indicated diagnostic procedures are performed depending on the patient's clinical state in&#xD;
      order to reach a diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1989</start_date>
  <completion_date>January 2004</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Achlorhydria</condition>
  <condition>Gastrinoma</condition>
  <condition>Zollinger Ellison Syndrome</condition>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility criteria not identified in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McArthur KE, Collen MJ, Maton PN, Cherner JA, Howard JM, Ciarleglio CA, Cornelius MJ, Jensen RT, Gardner JD. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):939-44. doi: 10.1016/s0016-5085(85)80011-1.</citation>
    <PMID>3972233</PMID>
  </reference>
  <reference>
    <citation>Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):1026-33. doi: 10.1016/s0016-5085(85)80024-x.</citation>
    <PMID>2857672</PMID>
  </reference>
  <reference>
    <citation>Vinayek R, Howard JM, Maton PN, Wank SA, Slaff JI, Gardner JD, Jensen RT. Famotidine in the therapy of gastric hypersecretory states. Am J Med. 1986 Oct 24;81(4B):49-59. doi: 10.1016/0002-9343(86)90600-5.</citation>
    <PMID>2877575</PMID>
  </reference>
  <verification_date>January 2004</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>March 4, 2008</last_update_submitted>
  <last_update_submitted_qc>March 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2008</last_update_posted>
  <keyword>Stomach</keyword>
  <keyword>Hypersecretion</keyword>
  <keyword>Hyposecretion</keyword>
  <keyword>Gastrinoma</keyword>
  <keyword>Zollinger-Ellison Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrinoma</mesh_term>
    <mesh_term>Zollinger-Ellison Syndrome</mesh_term>
    <mesh_term>Achlorhydria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

